Five hospitals say Lilly cut off tens of millions in 340B discounts until they hand over patient data
Five Massachusetts hospitals say Eli Lilly cut off tens of millions in 340B drug discounts until they surrender patient claims data to a private-equity-owned platform. Lilly calls it fraud policing, and the same gross-to-net machinery under dispute just produced a record $24.4 billion quarter.
Vincent Jiang · 3 min read
Five Massachusetts hospitals walked into US District Court in Boston on October 28, 2026, and accused the first trillion-dollar drugmaker of a shakedown 1. Massachusetts General, Brigham and Women's, Salem, UMass Memorial Medical Center and UMass Memorial Health-Harrington say Eli Lilly−3.65% — Eli Lilly, down 3.65 percent as of its last quote withheld 340B discounts worth tens of millions of dollars a year until they hand over patient claims data, and the complaint does not mince words: "corporate extortion," Lilly holding "vital 340B drug savings hostage" 1.
Dr. Patrick Gordan, Salem Hospital's associate chief medical officer, gave the ward-level version: 340B savings keep community health centers open, bring cancer screenings to neighborhoods by van, and no hospital should trade patient trust for them 1.
A statutory discount now comes with a toll booth
The 340B program is federal law, not a contract: manufacturers must sell outpatient drugs at deep discounts to organizations serving the uninsured and poor 2. Lilly announced in January that it would require claims-level data before honoring those prices, and first enforced it on a subset of hospitals in June 2.
The data must flow through 340B ESP, which the complaint calls "a unilaterally selected, private-equity-owned third-party platform," where de-identification is superficial, data can be used beyond integrity review, Lilly's liability is capped at $100, and the hospitals carry the full HIPAA compliance risk 2. At UMass Memorial, the savings fund free care and dental services at 28 public schools 1.
Lilly's defense, and an industry copying it
Lilly, which runs a $700 million research center in Boston, says the two largest hospital systems in Massachusetts "want to profit from it without transparency," sitting on data they already give insurers daily 1. The company says the data is needed to catch hospitals double-dipping 340B savings against Medicaid on the same patients 1.
By June, Lilly said 70% of covered entities buying its drugs, about 2,350 organizations, had already submitted in-house claims data 3. Novo Nordisk−4.62% — Novo Nordisk, down 4.62 percent as of its last quote imposed a similar requirement effective April 1 3. Missouri's attorney general sent Lilly a cease-and-desist on October 26 after the drugmaker cut the University of Missouri Health Care's discounts in July; that system complied 2.
Lilly argues in the earlier suits, brought by Tampa General and Dartmouth's Mary Hitchcock hospital, that state-law claims are preempted and the dispute belongs with HRSA, the federal agency that runs 340B; neither judge has ruled 3. The cost of refusal is on the record: Lilly pulled Tampa General's discounts on June 18 and the hospital's per-unit Mounjaro price jumped overnight from $750.52 to $1,019.74, up 35.9%, an estimated $24.7 million a year 3.
Read the complaint next to the earnings release
Lilly's Q3 2026 revenue rose 39% to $24.397 billion, and the company raised full-year guidance to $91 billion to $92 billion, a $5.5 billion midpoint increase 4. About $900 million of the quarter was not demand: $410 million in Jardiance milestones, none left after this, plus favorable rebate and discount adjustments 4.
The growth mix is the tell: volume up 53%, realized prices down 15% 4. Discounts and rebates are precisely the gross-to-net line this fight squeezes, so the policy Lilly is defending and the record quarter rest on the same machinery. Investors shrugged for now: shares climbed 2.32% to $1,442.01 in premarket trading on November 4 5. (The Inference charted Lilly's obesity duel with Novo on September 26 and its Dutch factory build-out on October 5; both predate this filing 5.)
Revenue doubled in two years while realized prices fell
Revenue doubled in two years, and the record quarter rests on the disputed discount line
Data
| Revenue | |
|---|---|
| Q3 '24 | 11.44 |
| Q4 '24 | 13.53 |
| Q1 '25 | 12.73 |
| Q2 '25 | 15.56 |
| Q3 '25 | 17.6 |
| Q4 '25 | 19.29 |
| Q1 '26 | 19.8 |
| Q2 '26 | 22.97 |
| Q3 '26 | 24.4 |
The 39% quarter is volume buying through falling prices
Lilly's record quarter is volume paying for a 15% slide in realized prices
Data
| Value | |
|---|---|
| Volume, % YoY | 53 |
| Revenue, % YoY | 39 |
| Realized prices, % YoY | -15 |
What decides it
No judge has ruled on the injunction requests in the Tampa or New Hampshire cases 3, and the Massachusetts complaint adds a consumer-protection claim with damages sought above the 340B ceiling price 2. Watch the first preliminary-injunction ruling. If Lilly holds, every manufacturer gets the same toll booth on a statutory discount, collected hospital by hospital. If the hospitals hold, the discount flows with no string attached, and the data-for-pricing swap dies in Boston.
Get Health by email, free
AI in medicine, pharma and biotech. In our daily email, every weekday.
